micro-community-banner
 
  • Saved

4yr

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics - PubMed

Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34208705/

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) represents approximately 5% of Hodgkin lymphoma and typically affects children and young adults. Although the overall prognosis is favorable, variant growth patterns in NLPHL...

  • 4yr
    One of the most challenging mimics of this disease is T cell rich DLBCL and I always recommend to referring physicians a 2nd pathology opinion given the overlapping pathological and Show More
  • Saved

4yr

Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement - PubMed

Impact of High-Dose Methotrexate on the Outcome of Patients with Diffuse Large B-Cell Lymphoma and Skeletal Involvement - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34204600/

Diffuse large B-cell lymphoma (DLBCL) with extra nodal skeletal involvement is rare. It is currently unclear whether these lymphomas should be treated in the same manner as those without skeletal...

  • 4yr
    Prior studies have been conflicting on skeletal involvement as an independent risk factor for cns recurrence, so many would not provide cns prophylaxis solely on that basis. While interesting, Show More
  • Saved

4yr

An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment - PubMed

An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34212052/

1 First Clinical Medical College of Southern Medical University, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China. 2 Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730,...

  • 4yr
    Authors should be complemented on a complex immunogenetic study of the elusive tumor micro environment. Will require confirmation in future studies but an
  • 4yr
    Key Points • Conclusion: “Our study describes a novel prognostic IRG [immune-related genes] classifier with strong predictive power in DLBCL. Our findings provide valuable guidance for further analysis of DLBCL pathogenesis Show More
  • Saved

4yr
R/R DLBCL – Novel Treatments & Clinical Experiences

Nearly two-thirds of patients with newly diagnosed DLBCL are cured with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. A minority of those with relapsed disease are candidates for salvage chemotherapy followed by high dose therapy and autologous stem cell transplant (ASCT), however few attain long-term remission. Moreover, those with refractory disease have a median survival of 6 months, which presents a dire need for improved treatments in patients with this deadly presentation.


The emergence of new targeted agents and immunotherapies represents a sea change in the treatment landscape for B-cell lymphomas. Approvals of CAR T-cell therapy, the anti-CD19 monoclonal antibody tafasitamab (Monjuvi), and the antibody-drug conjugate polatuzumab (Polivy) now bring effective treatment options to those with relapsed/refractory disease. Tafasitamab is an Fc-enhanced, anti-CD19 monoclonal antibody that has exhibited single-agent activity in patients with relapsed or refractory B-cell malignancies. It is suggested to act synergistically with lenalidomide (Revlimid), and the immunotherapy dyad of tafasitamab and lenalidomide became the first FDA-approved therapy as second-line treatment of DLBCL. In the Phase II L-MIND study, 80 patients with relapsed/refractory DLBCL who were unsuitable for ASCT, attained an overall response rate (ORR) of 60%, and 43% of patients attained a complete response with a median duration of response 21.7 months and a median progression-free survival (PFS) of 12.1 months. Notably, median overall survival (OS) was not reached. Researchers observed responses in patients with both germinal center and nongerminal center DLBCL and the combination was found to be well tolerated.

What are your experiences with these novel treatments for DLBCL?
How do you advise your patients on prognosis and other concerns related to these novel treatments?

  • 4yr
    Tafasitamab plus lenalidomide in L-MIND study as reported in Lancet appears promising and may be option for patients not candidates for ASCT/ CAR T
  • 4yr
    Interesting and happy we have newer and novel therapies emerging, now the BIG question will be sequencing the treatments and assess how to achieve the most efficacious pathway, will one Show More

Show More Comments

  • Saved

4yr

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling - PubMed

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34163463/

Gain-of-function mutations of the TLR adaptor and oncoprotein MyD88 drive B cell lymphomagenesis via sustained NF-κB activation. In myeloid cells, both short and sustained TLR activation and NF-κB activation lead...